NEWS - Feb 23, 2022 Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential Read more
NEWS - Feb 10, 2022 Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference Read more
NEWS - Dec 22, 2021 Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry Read more
NEWS - Dec 14, 2021 Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option Read more
NEWS - Dec 8, 2021 Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Read more
NEWS - Dec 1, 2021 Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology Read more
NEWS - Nov 11, 2021 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results Read more
NEWS - Nov 9, 2021 Relmada Therapeutics to Present at the Jefferies London Healthcare Conference Read more
NEWS - Nov 4, 2021 Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021 Read more
